Item 8.01. Other Events. On October 1, 2021, the Company entered into a License Agreement (the "Agreement") with Takeda Pharmaceuticals USA, Inc. ("Takeda"). Under the Agreement, the Company agreed to grant Takeda an exclusive license to the Company's ImmTOR technology initially for two specified disease indications within the field of lysosomal storage disorders. Under the terms of the Agreement, the Company is entitled to receive an undisclosed upfront payment and up to $1.124 billion in future additional payments over the course of the partnership that are contingent on the achievement of development or commercial milestones or Takeda's election to continue its activities at specified development stages. The Company is also eligible for tiered royalties on future commercial sales of any licensed products.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses